Blood Contaminants Act 1985

Definitions and scope. The Act’s operative definitions are in s 3(1) and determine its mechanics. An “approved blood test” is a test using a method and equipment approved by the Minister (s 3(1)). An “approved supplier” is either the Australian Red Cross Society (defined as “the Society”) or a hospital or other body approved by the Minister for the purposes of the Act (s 3(1)). “Blood product or product” is any extract or derivative of blood; “donor” is a person who gives blood for transfusion (s 3(1)). A “prescribed contaminant” is an organism or substance declared by the Minister by notice in the Gazette (s 3(1)). The Act applies where blood or a blood product “is to be used for transfusion” (s 3(2)).

Procedural safeguards. The Act prescribes a short sequence of procedural duties for approved suppliers in relation to donations. Before taking blood the supplier must secure a donor declaration in a Minister‑approved form (s 4(1)(a)). After collection the supplier must cause approved blood tests to be carried out as soon as practicable (s 4(1)(b)). If an approved blood test indicates the presence of a prescribed contaminant, the supplier must dispose of the blood and any blood product in a Minister‑approved manner (s 4(1)(c)). If tests do not indicate the presence of a prescribed contaminant, the supplier must issue a certificate certifying that result (s 4(1)(d)). Suppliers may only supply blood or blood products if the blood was taken by them (or the product manufactured from blood taken by them) or if acquired from a Minister‑approved source (s 4(2)). If an approved supplier has reasonable cause to suspect that blood or a blood product it supplied may be contaminated, it must take “all reasonable steps” to ensure the material is not used for transfusion (s 4(3)).

Conditional immunity. Section 5 creates the core legal consequence of compliance: where a prescribed contaminant or a disease attributable to a prescribed contaminant is transmitted by reason of transfusion and the blood or product was supplied by an approved supplier, “no civil or criminal liability” in respect of the transmission attaches to the donor, the supplier or a person who carried out the transfusion (s 5(1)). The immunity is lost if a donor knowingly makes a false declaration (s 5(2)) or if an approved supplier fails to observe a requirement of the Act in relation to the blood or blood product (s 5(3)). Those two subsections are the Act’s built‑in exceptions to the statutory immunity.

Ministerial control and administrative design. The Minister controls the content of several operative concepts and approvals: methods and equipment for approved blood tests, persons or bodies that qualify as approved suppliers, the list of prescribed contaminants (via Gazette notice), disposal methods, and the approval of sources from which suppliers may acquire blood or blood products (s 3(1); s 4(1)(a)-(d); s 4(2)). The Minister may delegate powers and functions to particular persons or office‑holders, and may allow further delegation if the instrument so provides (s 6(1)-(2)); delegations are revocable and may be absolute or conditional (s 6(3)).

Operational triggers and evidentiary artifacts. The Act builds a small evidentiary regime around certificates and declarations. Donor compliance requires a Minister‑approved declaration to be signed (s 4(1)(a)); supplier compliance produces a certificate where tests are negative (s 4(1)(d)). The combination of a signed declaration, test records and a certificate appears to be the statutory pathway to establish entitlement to the immunity in s 5(1).

Temporal and administrative flexibility. Several operative standards are expressed in open or subjective terms: “as soon as practicable” for timing of testing (s 4(1)(b)); “reasonable cause to suspect” and “all reasonable steps” for post‑supply precautionary obligations (s 4(3)); approval by notice in the Gazette for prescribed contaminants (s 3(1)). Those formulations embed administrative discretion and require suppliers to monitor ministerial instruments and exercise judgment.

Approved suppliers. The Act’s duties and the principal statutory immunity surround “approved suppliers” as defined in s 3(1). That category includes the Australian Red Cross Society (the Society) and any hospital or “other body” that the Minister approves for the purposes of the Act. Approved suppliers are the legal actors who take blood, cause testing, issue certificates, dispose of contaminated blood in Minister‑approved ways, acquire blood from Minister‑approved sources, and supply blood or blood products for transfusion (s 3(1); s 4(1)-(3)). The immunity in s 5(1) expressly attaches to approved suppliers where the relevant conditions are met, and s 5(3) expressly removes that protection where the supplier fails to observe the Act’s requirements.

Donors. Donors are persons who give blood for the purpose of transfusion (s 3(1)-(2)). The Act requires a donor to sign a declaration in a Minister‑approved form before blood is taken (s 4(1)(a)). A donor who has complied with that requirement and whose blood or blood product, supplied by an approved supplier, transmits a prescribed contaminant will generally be protected from civil or criminal liability under s 5(1). That protection is lost, however, if the donor knowingly makes a false declaration (s 5(2)).

Persons who carry out transfusions. The Act expressly extends the statutory protection to “a person who carried out the transfusion” where a prescribed contaminant or disease attributable to a prescribed contaminant is transmitted by reason of transfusion of blood or a blood product supplied by an approved supplier (s 5(1)). Thus clinicians, transfusion technicians and hospitals performing transfusions will be within the immunity’s scope so long as the statutory conditions are satisfied.

Minister and delegated actors. The Minister is the decision maker who approves test methods and equipment, declares prescribed contaminants by Gazette notice, approves suppliers and approved sources, and approves disposal methods (s 3(1); s 4(1)(c); s 4(2)). Section 6 permits the Minister to delegate powers and functions to a particular person or body or to the person for the time being holding an office, and to authorise further delegation if the instrument allows (s 6(1)-(2)). Delegates therefore implement many of the administrative choices that shape who qualifies as an approved supplier and what test methods and disposal arrangements are acceptable.

Other entities indirectly affected. Entities that manufacture blood products from supplied blood are affected because s 4(2) conditions the lawful supply of a blood product on whether the blood from which it was manufactured was taken by the supplier (or the product acquired from a Minister‑approved source). Laboratories performing approved blood tests will be affected because the Act requires suppliers to cause approved blood tests , defined by Minister approval of methods and equipment , to be carried out as soon as practicable after collection (s 4(1)(b)). Producers, transporters and storage facilities are affected through the duty to ensure a product’s supply source is approved and through the requirement to take reasonable steps to prevent use where contamination is suspected (s 4(2)-(3)).

Persons excluded from protection. The statutory immunity is not absolute: donors who knowingly make false declarations are excluded (s 5(2)), and approved suppliers who fail to observe statutory requirements lose the protection (s 5(3)). The Act therefore creates a conditional shield that shifts risk away from actors who follow the Act’s procedural steps and onto those who do not.

Duties placed on approved suppliers. The Act places a discrete set of duties on an approved supplier whenever it takes or proposes to take blood for transfusion (s 4(1)). Those duties are (a) to obtain a signed donor declaration in a form approved by the Minister before taking the blood (s 4(1)(a)); (b) to have approved blood tests carried out “as soon as practicable” after taking the blood (s 4(1)(b)); (c) to dispose of any blood and blood products that test positive for a prescribed contaminant in a Minister‑approved manner (s 4(1)(c)); and (d) to issue a certificate certifying that approved blood tests did not indicate a prescribed contaminant where that is the test outcome (s 4(1)(d)). The Act further obliges an approved supplier not to supply blood or a product for transfusion unless the blood was taken by the supplier or the product was manufactured from blood taken by the supplier, or the blood or product was acquired from a Minister‑approved source (s 4(2)). If the supplier has reasonable cause to suspect that blood or a blood product it supplied may be contaminated, it must take “all reasonable steps” to ensure that the blood or blood product is not used for transfusion (s 4(3)). The Act uses open standards (“as soon as practicable”; “reasonable cause to suspect”; “all reasonable steps”) rather than hard timeframes or prescriptive checklists (s 4(1)(b); s 4(3)).

Duties on donors. The Act requires a donor to sign a declaration in a form approved by the Minister before blood is taken (s 4(1)(a)). That signed declaration is a precondition for the supplier to lawfully take blood under the Act’s mechanics. Beyond the requirement to sign, the Act does not specify the contents of the form; the content is a Ministerial matter.

Rights and immunities. Section 5 creates the principal right in the statute: where a prescribed contaminant or a disease attributable to a prescribed contaminant is transmitted by reason of transfusion of blood or a blood product supplied for transfusion by an approved supplier, “no civil or criminal liability in respect of the transmission of the contaminant or disease attaches to a donor, the supplier or a person who carried out the transfusion” (s 5(1)). That is a statutory immunity from civil and criminal liability for those persons, conditioned on the supplied blood or product being supplied by an approved supplier and the Act’s procedural requirements being observed.

Exceptions to immunity. The Act places two express exceptions. First, a donor who knowingly makes a false declaration is not entitled to the protection (s 5(2)). Second, an approved supplier who fails to observe a requirement of the Act with respect to the blood or blood product, or blood from which the product was manufactured, is not entitled to the protection (s 5(3)). The exceptions operate as statutory exclusions of the immunity rather than as separate criminal offences or prescriptive penalties within the Act.

Administrative powers and delegations. The Minister has the authority to approve test methods and equipment, to declare prescribed contaminants by Gazette notice, to approve bodies and sources and to approve disposal methods; the Minister may delegate these powers and functions to particular persons or office‑holders and may authorise further delegation if the instrument permits (s 3(1); s 4(1)(c); s 4(2); s 6(1)-(2)). Delegations are revocable at will and do not derogate from the Minister’s power (s 6(3)). Those administrative powers structure the rights and duties because the operative standards and thresholds (approved test methods, approved suppliers, prescribed contaminants) are ministerial instruments.

Evidentiary artefacts as rights enablers. The Act’s statutory right to immunity is enabled by documentary steps: the donor declaration and the supplier’s certificate where tests are negative (s 4(1)(a), (d)). Those documents are the statutory indicia that a supplier and donor have complied with the Act’s requirements and thus that the immunity in s 5(1) should apply.

Matters not specified in the Act. The Act does not itself specify a sanction regime within its text (for example, there are no prescribed fines or administrative penalties contained in the Act), other than the express loss of immunity in the events specified (s 5(2)-(3)). Nor does the Act prescribe the content of the Minister‑approved forms or the precise standards for “reasonable steps” or “as soon as practicable” (s 4(1)(b); s 4(3)). Those operational details are left to ministerial approval and administrative practice.

Statutory design: immunity rather than internal penalties. The Act’s primary legal mechanism is to create a statutory immunity (a negative protection) rather than to establish a new set of criminal offences or a graduated administrative penalty regime within the statute. Where a prescribed contaminant or a disease attributable to a prescribed contaminant is transmitted by reason of transfusion and the blood or blood product was supplied by an approved supplier, “no civil or criminal liability” attaches to the donor, the supplier or the person who carried out the transfusion (s 5(1)). The Act therefore removes potential civil and criminal exposure for those actors when the specified conditions are met.

Conditional removal of immunity as enforcement lever. The Act contains two express conditions that remove the immunity. First, a donor who knowingly makes a false declaration is “not entitled to the protection of this section” (s 5(2)). Second, an approved supplier who “fails to observe a requirement of this Act in relation to the blood or blood product or in relation to blood from which the blood product was manufactured” is similarly not entitled to protection (s 5(3)). Those provisions operate as the Act’s internal enforcement mechanisms: failure to comply with specified procedural duties exposes actors to civil or criminal liability that the Act would otherwise exclude.

Absence of internal penalty prescriptions and inspection powers. The Act does not itself prescribe penalties (such as fines or imprisonment) for breaches of the procedural duties in s 4. It also does not create inspection powers, registration fees, licensing conditions with penalty schedules, or an enforcement agency within the Act’s text. The Act provides only that failure to observe the statutory requirements removes the immunity; it does not specify who enforces the statutory duties in the first instance or the mechanism for proving a breach within the statute. The absence of express administrative penalties or an inspection regime means that the Act’s enforcement effect depends on existing civil and criminal liability frameworks outside the text; the Act’s practical enforcement consequences will therefore flow from whether other civil or criminal causes of action are pursued when immunity is excluded (the Act itself does not specify those external causes).

Proof and evidential posture. Given the Act’s reliance on documentary steps (the donor declaration and the supplier’s certificate) and conditionally expressed duties (“as soon as practicable”, “all reasonable steps”), enforcement proceedings will turn on factual proof of compliance or breach. The Act does not set evidentiary rules, burden‑allocation or limitation periods; it sets statutory conditions that determine whether exemption from liability is available (s 4(1)(a)-(d); s 4(3); s 5(1)-(3)).

Ministerial approvals and enforceable standards. The Minister’s approvals (test methods and equipment; approved sources; approved disposal methods; the definition of prescribed contaminants by Gazette notice) serve as the Act’s normative anchors. Compliance with the Act requires adherence to those ministerial approvals; conversely, failure to follow those approvals is captured by s 5(3) as a ground for losing immunity. The Act therefore uses ministerial approvals as the enforcement touchpoints, while leaving sanctioning to civil or criminal processes outside the statute where immunity is excluded.

Delegation and administrative accountability. Section 6 permits delegation of the Minister’s powers and functions and allows further delegation if the instrument of delegation so provides (s 6(1)-(2)). Delegations are revocable and do not derogate from the Minister’s power (s 6(3)). The Act does not, however, set out administrative review or appeal rights against ministerial approvals or decisions within its text. The scope for administrative review therefore depends on broader administrative law frameworks external to the Act; the Act itself does not create specific appellate or review pathways.

Limited cross‑references within the text. The Act’s text supplied contains only internal references to the Minister’s approval functions and to the Australian Red Cross Society as the named “Society” (s 3(1)). It does not expressly refer to other named South Australian statutes, national health legislation, negligence law, public health acts, or product liability statutes within the operative sections (s 3-6). The legislative history section contains a general note warning that references to other legislation or instruments in the legislation may not be automatically updated and therefore may be obsolete, which signals that cross‑references historically present may have changed over time and needs checking against current instruments (Legislative history, Notes).

Immunity as a statutory carve‑out. The Act creates a statutory bar to civil and criminal liability for donors, approved suppliers and persons carrying out transfusions under the circumstances set out in s 5(1). That bar operates within the ambit of the Act’s terms: it applies where a prescribed contaminant or disease attributable to such a contaminant is transmitted by reason of transfusion of blood or a blood product supplied by an approved supplier (s 5(1)). The effect of that statutory bar is to displace or remove exposure to civil or criminal liability in the circumstances described; the Act does not itself declare the common law or any particular statute to be impliedly repealed. The text does not state whether the immunity is intended to be exhaustive or whether other statutory schemes take precedence, so the interaction with particular external liability regimes is not expressed in the Act.

Ministerial instruments as operational connectors. The Act relies on ministerial instruments , approvals, approvals by notice in the Gazette , as operational connectors to administrative detail. For example, “prescribed contaminant” is an organism or substance declared by the Minister by Gazette notice (s 3(1)), and “approved blood test” requires Ministerial approval of method and equipment (s 3(1)). Those ministerial instruments are points where the Act will interface with technical health standards, laboratory practices and possibly national guidelines, but the text supplies no normative content for those instruments.

Delegation and administrative law. Section 6 permits delegation of the Minister’s powers and functions and contemplates further delegation in the instrument (s 6(1)-(2)). That interacts with administrative law principles about delegation, revocation and decision‑making accountability, although the Act does not itself specify procedural safeguards for delegations; the Act’s delegations are exercisable "to a particular person or body" or to the person holding a particular office (s 6(1)). The Act therefore embeds administrative discretion while leaving procedural protections and review mechanisms to broader administrative law frameworks (not specified inside the Act).

Legislative history and amendments. The legislative history records amendments (notably in 2000 and a substitution in 2025 to be effective 4 January 2026 for the definition or scope of “prescribed contaminant”), and records that s 2 was omitted under the Legislation Revision and Publication Act 2002 (Legislative history: Principal Act and amendments; Provisions amended). Those amendments will affect how the Act operates in relation to other statutes and instruments after the stated commencement dates; for interaction with other laws, users must consult the consolidated and current version and the relevant ministerial instruments.

What the Act does not do within its text. The Act does not create a standalone enforcement apparatus (inspectors, fixed penalty notices, licensing offence schedules) within the text. It does not supply the technical content of approved tests, approved forms, the list of prescribed contaminants, or approved disposal methods; those are delegated to the Minister. The Act does not itself provide appeal mechanisms or administrative review pathways; any such interactions must be sought in external administrative law or other statutory frameworks.

Principal enactment and early commencement. The Blood Contaminants Act 1985 was assented to on 7 November 1985, with recorded commencement entries showing a commencement date for s 2 on 1 July 1985 (Legislative history: Principal Act and amendments; Year 1985 No 99). The Act’s operative sections as presented,s 3, s 4, s 5 and s 6,are the parts currently reproduced in the supplied text.

2000 amendments. The South Australian Health Commission (Administrative Arrangements) Amendment Act 2000 (No 34 of 2000) made multiple textual amendments with commencement noted as 6 July 2000 (Legislative history). The “Provisions amended” table in the legislative history lists precise alterations effected by Sch 1 cl 2 of that Act: the definitions for “approved blood test”, “approved supplier”, and “prescribed contaminant” were amended by Sch 1 cl 2(a), (b) and (d) respectively, and “the Commission” was deleted by Sch 1 cl 2(c) (Provisions amended). Section 4(1) and (2) were also amended by Sch 1 cl 2(e), and section 6 was inserted by Sch 1 cl 2(f) (Provisions amended). The 2000 amendments therefore updated definitions and inserted the delegation regime now codified at s 6.

Omission under revision. The legislative history records that s 2 of the Act was omitted under the Legislation Revision and Publication Act 2002 (Provisions amended). The legislative history cautions that references to other legislation or titles may not be automatically updated (Notes), which is relevant to any historical cross‑references that may have been in s 2 or the original Act text.

2025 substitution and forthcoming change. A later amendment appears in the legislative history: Statutes Amendment (Health and Wellbeing) Act 2025 (No 69 of 2025), assented 4 December 2025, with Part 5 (s 9) commencing on 4 January 2026 by s 2(2). The Provisions amended table shows that “prescribed contaminant” was substituted by 69/2025 s 9 with effect 4.1.2026 (Provisions amended). That indicates a forthcoming textual change to the definition or scope of “prescribed contaminant” effective 4 January 2026. The legislative history also notes the dates of assent and commencement for each amending instrument.

Record of historical versions. The legislative history lists the historical version dated 6 July 2000 as a recorded historical version (Historical versions). The table of amendments shows which provisions were varied and the instrument and clause that made the change (Provisions amended). New entries are annotated in bold and deleted provisions are indicated in italics in the supplied legislative history extract.

Practical effect for practitioners. The Act’s text and legislative history identify three key amendment points to track: the 2000 amendments which adjusted definitions and inserted the delegation power; the omission of s 2 under revision in 2002; and the 2025 enactment substituting the definition of “prescribed contaminant” effective from 4 January 2026. Any compliance or advisory work must therefore verify the operative text as at the relevant date and inspect ministerial instruments (Gazette notices and approvals) that flesh out definitions and technical standards.

No judicial decisions or administrative appeals are recorded in the supplied Act text or its legislative history. The legislation as supplied contains no citations to reported cases, no references to court determinations, and no exposition of how courts have interpreted the Act’s conditional immunity or procedural duties. The legislative history lists statutory amendments and notes, but it does not report litigation.

Implications of the absence. The absence of any litigation history in the Act’s text means that practitioners cannot rely on judicially developed interpretive guidance contained within the statute’s text as provided. Key interpretive questions remain untested by reported decisions in the materials supplied, including but not limited to: what evidentiary standard proves a donor’s “knowing” false declaration under s 5(2), what factual showings will satisfy or rebut that a supplier “observed a requirement of this Act” for purposes of s 5(3), how courts will construe “as soon as practicable” for timing of tests (s 4(1)(b)), and how “all reasonable steps” will be appraised in light of supplier actions on discovery of a reasonable suspicion of contamination (s 4(3)). None of those interpretive questions are answered in the supplied statute or legislative history.

What that means for advisory practice. Where statutory wording is open‑ended (for example, “reasonable cause to suspect”, “all reasonable steps”, “as soon as practicable”) the absence of authoritative judicial construction increases reliance on the text of ministerial instruments (approved test methods, approved disposal methods, Gazette notices declaring prescribed contaminants) and on contemporaneous regulatory guidance. Because the Act vests substantive operational authority in the Minister (s 3(1); s 4(1)(c); s 4(2); s 6), administrative instruments and departmental practice will be primary sources to determine compliance expectations in the absence of reported judicial answers. The supplied Act does not identify any specific administrative or judicial review outcomes that clarify those standards.

Due diligence and risk allocation. Given no litigation history is supplied, practitioners advising clients should insist on documentary evidence of compliance with the Act’s procedural elements where the immunity in s 5(1) is likely to be relevant: Minister‑approved donor declaration forms, records showing approved testing methods and results performed “as soon as practicable”, certificates issued where tests are negative, approvals for suppliers and for sources of supply, records of disposal where tests indicate contamination, and contemporaneous documentation of steps taken when a supplier has reasonable cause to suspect contamination (s 4(1)(a)-(d); s 4(2); s 4(3); s 5(1)-(3)). Those practical evidentiary steps are necessary to operationalise the statutory immunity described in s 5(1) in the absence of detailed judicial guidance within the supplied materials.

Prescribed Ministerial content is the Act’s normative core. The Act’s operative concepts depend on Ministerial approvals and Gazette declarations (s 3(1); s 4(1)(c); s 4(2)). Suppliers and advisers must note that the statute’s compliance requirements refer to external instruments whose content is not in the Act. The Act therefore creates a risk of operational uncertainty if suppliers fail to monitor Gazettes, Ministerial approvals or delegated instruments that define approved test methods, approved equipment, approved sources and approved disposal methods (s 3(1); s 4(1)(c); s 4(2)). The Act does not set the content of those instruments.

Donor declaration as a gateway to immunity. The statutory sequence makes the donor declaration a gateway requirement: the blood “shall not be taken unless the donor has signed a declaration in a form approved by the Minister” (s 4(1)(a)). A supplier that proceeds without such a signature risks losing the statutory shield in s 5(1) because s 5(3) removes protection where the supplier fails to observe a requirement of the Act. The Act does not specify the content of the declaration; the form’s content is a Ministerial matter. Practically, if a donor signs a declaration that is later found to be false and that falsehood was knowing, the donor loses the Act’s protection (s 5(2)).

Timing ambiguities. The Act requires approved blood tests “as soon as practicable after taking the blood” (s 4(1)(b)). “As soon as practicable” is an open standard; the Act supplies no clock, no maximum time window and no prescriptive testing protocol inside the text. That leaves suppliers to interpret timing in the context of the Minister’s approved methods and equipment for approved blood tests, and to justify timelines if the statutory immunity is contested (s 3(1); s 4(1)(b)).

Vague standards for suspicion and steps. The duty to take “all reasonable steps” to ensure that suspected contaminated blood or blood products are not used (s 4(3)) is expressed in subjective and objective terms without statutory examples. What steps are “reasonable” will be fact‑specific and dependent on technical practice, but the Act contains no checklist. That increases compliance and evidentiary burdens on suppliers who must document the steps taken when reasonable suspicion arises.

Traceability and manufacturing chains. Section 5(3) removes immunity where a supplier fails to observe an Act requirement “in relation to the blood or blood product or in relation to blood from which the blood product was manufactured” (s 5(3)). The insertion of the manufacturing chain into the failure‑of‑compliance provision extends potential exposure upstream: a supplier of a blood product can lose immunity for failures relating both to the product itself and to the blood from which the product was manufactured. That creates an operational need to maintain upstream traceability and records that demonstrate compliance at each step of manufacture and supply.

Disposal and certificate approvals. The Act requires disposal of contaminated material “in a manner approved by the Minister” (s 4(1)(c)) and requires issuing certificates where tests are negative (s 4(1)(d)). Failure to follow the Minister’s approved disposal method or to issue a required certificate undermines the supplier’s entitlement to statutory protection (s 5(3)). The Act does not specify what a compliant certificate must contain; material omissions or inaccurate certificates could jeopardise immunity.

Donor falsehood standard. The Act disqualifies a donor who “knowingly makes a false declaration” from protection under s 5(2). The word “knowingly” introduces a mens rea element for donors’ loss of immunity. That raises evidentiary challenges in proving subjective knowledge, and creates a potential defence where donors can show honest mistakes rather than knowledge. The Act does not define “knowingly” or supply evidentiary presumptions.

Delegation risks and accountability. Section 6 permits delegation of ministerial powers and further delegation if the instrument allows (s 6(1)-(2)). Delegations are revocable and do not derogate from the Minister’s power (s 6(3)). In practice, that can create distributed administrative decision‑making about approvals, which can complicate lines of accountability. The Act does not prescribe review pathways for ministerial delegations or decisions made under delegated authority.

No internal penalty schedule. The Act contains no internal fixed penalty or administrative sanction framework for non‑observance aside from the removal of immunity. Enforcement therefore relies on external legal processes when immunity is lost. That can create legal uncertainty about the practical consequences of particular breaches because the Act does not specify which civil or criminal liabilities will attach in any particular circumstance once immunity is excluded (s 5(2)-(3)).

Amendments to “prescribed contaminant”. The legislative history shows that the definition or content of “prescribed contaminant” was substituted by 69/2025 s 9 effective 4 January 2026 (Provisions amended). Suppliers must monitor that change because the identity of what counts as a prescribed contaminant is a Ministerial/legislative variable that determines when the statutory protections and duties apply (s 3(1); Legislative history).

Establish and record approval evidence. Maintain contemporaneous documentary evidence of ministerial approvals relevant to operations: the Minister’s approval of the supplier (approval to be an “approved supplier”), the Minister’s approval of test methods and equipment (defining “approved blood test”), and any Ministerial Gazette notices declaring prescribed contaminants (s 3(1); s 4(2)). Because the Act’s protective regime depends on Ministerial approvals, hold copies of approvals and record their dates and scope.

Donor declaration process. Ensure that no blood is taken unless the donor has signed the donor declaration in the form approved by the Minister (s 4(1)(a)). Retain signed declaration forms in a secure record system tied to the donation batch and the subsequent testing results. Given s 5(2) disqualifies donors who “knowingly” make false declarations, ensure the declaration form is clear about the consequences and that donors have the opportunity to disclose relevant information accurately before signing.

Testing workflow and timing. Implement a documented protocol to cause approved blood tests to be carried out “as soon as practicable after taking the blood” (s 4(1)(b)). Because the Act leaves timing open, create a written operational standard that aligns with the Minister’s approved test methods and equipment, and that explains delays (if any) in terms that would satisfy a reasonableness assessment. Keep time‑stamped records showing collection, transportation, testing, and results, linked to each donation and any downstream blood products.

Certificate issuance and retention. Where approved blood tests do not indicate the presence of a prescribed contaminant, issue the statutory certificate required by s 4(1)(d) and retain a copy with the donation record. Ensure the certificate content satisfies any Ministerial guidance, and store certificates to demonstrate compliance where immunity may be asserted under s 5(1).

Supply source control and traceability. Do not supply blood or blood products for transfusion unless the blood was taken by the supplier, the product manufactured from blood taken by the supplier, or the blood/product was acquired from a source approved by the Minister (s 4(2)). Maintain supplier‑to‑supplier traceability records and evidentiary chains showing the origin of the blood used in manufactured products, because s 5(3) links immunity to compliance both with respect to the product and the blood from which the product was manufactured.

Responding to suspected contamination. If there is reasonable cause to suspect that blood or a blood product supplied by the supplier may be contaminated, take all reasonable steps to ensure it is not used for transfusion (s 4(3)). Document actions taken immediately: recall notices, quarantine instructions, notifications to receiving facilities, traceability checks, destruction or sequestration steps, and communications to regulators where relevant. The phrase “all reasonable steps” requires contemporaneous and auditable action.

Disposal in approved manners. Where an approved blood test indicates the presence of a prescribed contaminant, dispose of the blood and any product of the blood “in a manner approved by the Minister” (s 4(1)(c)). Record the disposal method, approvals relied on, date, personnel involved, and any physical destruction or decontamination certificates.

Monitor ministerial instruments and delegate authorisations. Because many operative standards are set by the Minister, suppliers should establish a process to monitor Gazettes and ministerial instruments for updates to the list of prescribed contaminants, to approved testing methods and equipment, and to approvals of suppliers or sources (s 3(1); s 4(1)(b); s 4(2)). Document compliance with delegations if approvals are exercised by delegates under s 6. Keep record of which official signed any approval and the instrument authorising delegation.

Training and governance. Train staff on the statutory steps and the evidentiary significance of donor declarations and certificates. Implement governance checks to ensure testing is carried out in accordance with Ministerial approval and that retention of records meets the needs of any future civil or criminal scrutiny under s 5(1)-(3).

Contractual and procurement safeguards. Where acquiring blood or blood products from third parties, contractually require the supplier to produce evidence of Ministerial approval as an approved source (s 4(2)). Include warranties and indemnities that reflect the statutory allocation of risk, with careful drafting to avoid promising a statutory immunity beyond the Act’s terms; ensure the contract requires notification and documentation if a supplier has reasonable cause to suspect contamination.

Audit and record retention policies. Maintain auditable records linking donor declarations, collection times, test timestamps, test methods and equipment used, test results, certificates issued, disposal records for contaminated materials, and approvals for sources and disposal methods. Those records constitute the primary evidence base to establish entitlement to the immunity in s 5(1) and to show compliance with Act requirements to avoid the disqualification in s 5(3).

Legal review and update processes. Given the Act’s amendment history (notably the substitution affecting “prescribed contaminant” effective 4 January 2026 per the legislative history), schedule periodic legal reviews to confirm the operative definitions and ministerial approvals remain current (Legislative history). Ensure that compliance programmes capture changes on or after the relevant commencement dates.

Documentation of decision‑making under open standards. For duties expressed in open terms (“as soon as practicable”, “reasonable cause to suspect”, “all reasonable steps”), maintain contemporaneous decision logs that explain why particular actions were taken and why they were proportionate and reasonable in the circumstances. Those logs will be the primary source material to support a claim that the supplier “observed a requirement of this Act” and so is entitled to the statutory protection under s 5(1).

Engage with the Ministerial office where necessary. If technical uncertainties exist about what constitutes an approved test method, approved equipment, an approved disposal method, or an approved source, seek clarification or formal approval from the Minister or the delegated authority under s 6, and keep written records of any such clarifying communications and approvals.